SCD and Parkinson disease: Targeting FA synthesis via SCD inhibition has already proven successful in reversing or preventing PD-relevant phenotypes in multiple diverse models23,32,35 and has entered human trials, but this approach does not address the role of FAs generated via lipid degradation.